A Phase I/II trial of glofitamab monotherapy in R/R MCL

A Phase I/II trial of glofitamab monotherapy in R/R MCL

Glofitamab and obinutuzumab in r/r MCLПодробнее

Glofitamab and obinutuzumab in r/r MCL

Glofitamab step-up dosing in R/R MCLПодробнее

Glofitamab step-up dosing in R/R MCL

GLOBRYTE: investigating glofitamab monotherapy in patients with R/R MCLПодробнее

GLOBRYTE: investigating glofitamab monotherapy in patients with R/R MCL

Phase II trial of acalabrutinib, lenalidomide and rituximab in patients with MCLПодробнее

Phase II trial of acalabrutinib, lenalidomide and rituximab in patients with MCL

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphomaПодробнее

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphoma

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCL

Phase II study of glofitamab in patients with R/R LBCLПодробнее

Phase II study of glofitamab in patients with R/R LBCL

Update on Phase I/II study of glofitamab monotherapy in R/R MCLПодробнее

Update on Phase I/II study of glofitamab monotherapy in R/R MCL

NP30179: Glofitamab monotherapy in R/R NHLПодробнее

NP30179: Glofitamab monotherapy in R/R NHL

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in R/R FLПодробнее

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in R/R FL

Phase Ib trial of R-CHOP plus iberdomide or golcadomide in aggressive B-cell lymphomaПодробнее

Phase Ib trial of R-CHOP plus iberdomide or golcadomide in aggressive B-cell lymphoma

The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R/R DLBCLПодробнее

The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R/R DLBCL

Hot updates in R/R MCL at ASH 2022: data on pirtobrutinib, glofitamab & zilovertamabПодробнее

Hot updates in R/R MCL at ASH 2022: data on pirtobrutinib, glofitamab & zilovertamab

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphomaПодробнее

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

Updates on glofitamab in MCLПодробнее

Updates on glofitamab in MCL

Highlights on first-line treatment of Mantle Cell Lymphoma: Primary results from SHINEПодробнее

Highlights on first-line treatment of Mantle Cell Lymphoma: Primary results from SHINE

Acalabrutinib monotherapy in R/R MCL: extended follow-up resultsПодробнее

Acalabrutinib monotherapy in R/R MCL: extended follow-up results

Results from a Phase I/II trial of pirtobrutinib and LV20.19 for patients with R/R lymphomasПодробнее

Results from a Phase I/II trial of pirtobrutinib and LV20.19 for patients with R/R lymphomas

Phase I/II study of zilovertamab and ibrutinib in MCL and CLLПодробнее

Phase I/II study of zilovertamab and ibrutinib in MCL and CLL